Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

Regeneron (REGN) announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors – carfilzomib or ...

Regeneron will report a decline in revenues this year due to the lack of COVID-19 antibody sales. Read why growth is set to resume in 2023.

Regeneron saw its sales rise in recent years, led by its Covid-19 multi-antibody therapy, which garnered $6 billion in 2021 sales. However, with the pandemic now behind us, sales declined in 2022.

Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in a late-stage trial, in the two to eight months period ...

Regeneron warned its popular antibody cocktail used to treat high-risk cases of COVID-19 may not be as effective against the new Omicron variant.. The New York-based pharmaceutical company said ...